A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/485 (2006.01) A61K 31/451 (2006.01) A61K 31/513 (2006.01) A61K 39/395 (2006.01) A61P 3/10 (2006.01) A61P 7/06 (2006.01) A61P 9/10 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2649710
The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists, such as methylnaltrexone or alvimopan. The disorders to be treated alone or in combiantion with for instance - anticancer agents (5-f luorouracil or bevacizumab) are i.a. cancer, diabetes, sickle cell anemia, vascular wound, proliferative retinopathy.
La présente invention concerne des procédés permettant d'atténuer, par exemple d'inhiber ou de réduire, la prolifération et la migration des cellules, en particulier la prolifération et la migration des cellules endothéliales y compris celles qui sont associées à l'angiogenèse, en utilisant des antagonistes des opioïdes, y compris, mais sans limitation, les antagonistes limités à la périphérie.
Garcia Joe G.n.
Lingen Mark
Moss Jonathan
Singleton Patrick A.
Yuan Chun-Su
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
The University Of Chicago
LandOfFree
Use of opioid antagonists to attenuate endothelial cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of opioid antagonists to attenuate endothelial cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of opioid antagonists to attenuate endothelial cell... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2064514